RU2476434C2 - Кристаллическая форма 1 2-((r)-2-метилпирролидин-2-ил)-1н-бензимидазол-4-карбоксамида - Google Patents

Кристаллическая форма 1 2-((r)-2-метилпирролидин-2-ил)-1н-бензимидазол-4-карбоксамида Download PDF

Info

Publication number
RU2476434C2
RU2476434C2 RU2010116397/04A RU2010116397A RU2476434C2 RU 2476434 C2 RU2476434 C2 RU 2476434C2 RU 2010116397/04 A RU2010116397/04 A RU 2010116397/04A RU 2010116397 A RU2010116397 A RU 2010116397A RU 2476434 C2 RU2476434 C2 RU 2476434C2
Authority
RU
Russia
Prior art keywords
benzimidazole
carboxamide
methylpyrrolidin
crystalline form
abt
Prior art date
Application number
RU2010116397/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2010116397A (ru
Inventor
Лоуренс КОЛАЦКОВСКИ
Original Assignee
Эбботт Лэборетриз
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40210712&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2476434(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Эбботт Лэборетриз filed Critical Эбботт Лэборетриз
Publication of RU2010116397A publication Critical patent/RU2010116397A/ru
Application granted granted Critical
Publication of RU2476434C2 publication Critical patent/RU2476434C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2010116397/04A 2007-10-12 2008-10-10 Кристаллическая форма 1 2-((r)-2-метилпирролидин-2-ил)-1н-бензимидазол-4-карбоксамида RU2476434C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97964307P 2007-10-12 2007-10-12
US60/979,643 2007-10-12
PCT/US2008/079441 WO2009049111A1 (en) 2007-10-12 2008-10-10 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 1

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2012147692/04A Division RU2012147692A (ru) 2007-10-12 2012-11-08 Кристаллическая форма 1 2-(r)-2-метилпирролидин-2-ил)-1н-бензимидазол-4-карбоксамида

Publications (2)

Publication Number Publication Date
RU2010116397A RU2010116397A (ru) 2011-11-20
RU2476434C2 true RU2476434C2 (ru) 2013-02-27

Family

ID=40210712

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2010116397/04A RU2476434C2 (ru) 2007-10-12 2008-10-10 Кристаллическая форма 1 2-((r)-2-метилпирролидин-2-ил)-1н-бензимидазол-4-карбоксамида
RU2012147692/04A RU2012147692A (ru) 2007-10-12 2012-11-08 Кристаллическая форма 1 2-(r)-2-метилпирролидин-2-ил)-1н-бензимидазол-4-карбоксамида

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2012147692/04A RU2012147692A (ru) 2007-10-12 2012-11-08 Кристаллическая форма 1 2-(r)-2-метилпирролидин-2-ил)-1н-бензимидазол-4-карбоксамида

Country Status (28)

Country Link
US (4) US8372987B2 (https=)
EP (2) EP2212327A1 (https=)
JP (4) JP2011500589A (https=)
KR (2) KR20100090769A (https=)
CN (2) CN101821270A (https=)
AU (1) AU2008310781B2 (https=)
BR (1) BRPI0816221A8 (https=)
CA (2) CA3006332A1 (https=)
CO (1) CO6280493A2 (https=)
CR (1) CR11368A (https=)
DK (1) DK2722046T3 (https=)
DO (1) DOP2010000099A (https=)
EC (1) ECSP10010150A (https=)
ES (1) ES2620299T3 (https=)
GT (1) GT201000080A (https=)
MX (1) MX350019B (https=)
MY (1) MY156691A (https=)
NZ (1) NZ583209A (https=)
PA (1) PA8798401A1 (https=)
PH (1) PH12012501636A1 (https=)
PL (1) PL2722046T3 (https=)
PT (1) PT2722046T (https=)
RU (2) RU2476434C2 (https=)
SG (1) SG185297A1 (https=)
TW (1) TWI422588B (https=)
UA (2) UA113277C2 (https=)
WO (1) WO2009049111A1 (https=)
ZA (1) ZA201002090B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY156691A (en) 2007-10-12 2016-03-15 Abbvie Bahamas Ltd 2-(r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline from 1
CA2696423A1 (en) 2007-10-12 2009-04-16 Guidong Zhu 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 2
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
CN105130961B (zh) * 2015-08-06 2018-02-16 苏州晶云药物科技有限公司 Abt‑888的晶型b及其制备方法和应用
CN106995436A (zh) * 2016-01-25 2017-08-01 重庆医药工业研究院有限责任公司 一种维利帕尼晶型a及其制备方法
US20190092756A1 (en) * 2016-03-09 2019-03-28 Crystal Pharmatech Co., Ltd. Crystalline form a of 2-[(2r)-2-methyl-2-pyrrolidyl]-1h-benzimidazole-7-carboxamide dihydrochloride and preparation method thereof
EP3275434B1 (en) 2016-07-27 2020-08-26 Sandoz Ag An extended release oral dosage form

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA006802B1 (ru) * 2001-09-26 2006-04-28 Авентис Фарма С.А. Замещенные производные бензимидазола и их применение для лечения злокачественной опухоли
US20060229289A1 (en) * 2005-04-11 2006-10-12 Gui-Dong Zhu 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1248869A2 (en) * 2000-01-07 2002-10-16 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
MY156691A (en) 2007-10-12 2016-03-15 Abbvie Bahamas Ltd 2-(r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline from 1
CA2696423A1 (en) * 2007-10-12 2009-04-16 Guidong Zhu 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 2

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA006802B1 (ru) * 2001-09-26 2006-04-28 Авентис Фарма С.А. Замещенные производные бензимидазола и их применение для лечения злокачественной опухоли
US20060229289A1 (en) * 2005-04-11 2006-10-12 Gui-Dong Zhu 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors

Also Published As

Publication number Publication date
BRPI0816221A8 (pt) 2015-09-22
EP2212327A1 (en) 2010-08-04
JP2019001811A (ja) 2019-01-10
CA3006332A1 (en) 2009-04-16
CN101821270A (zh) 2010-09-01
US20140024838A1 (en) 2014-01-23
RU2010116397A (ru) 2011-11-20
NZ583209A (en) 2012-06-29
MX2010003772A (es) 2010-04-21
CN105367554A (zh) 2016-03-02
ECSP10010150A (es) 2010-06-29
JP2011500589A (ja) 2011-01-06
SG185297A1 (en) 2012-11-29
EP2722046B1 (en) 2016-12-21
RU2012147692A (ru) 2014-05-20
PL2722046T3 (pl) 2017-06-30
US20130123317A1 (en) 2013-05-16
US9580410B2 (en) 2017-02-28
US8372987B2 (en) 2013-02-12
ZA201002090B (en) 2011-11-30
PT2722046T (pt) 2017-03-15
WO2009049111A1 (en) 2009-04-16
US8835647B2 (en) 2014-09-16
US20150148392A1 (en) 2015-05-28
GT201000080A (es) 2012-04-03
CA2696424C (en) 2018-07-10
CA2696424A1 (en) 2009-04-16
AU2008310781A1 (en) 2009-04-16
UA113277C2 (xx) 2017-01-10
CO6280493A2 (es) 2011-05-20
JP2017071618A (ja) 2017-04-13
MY156691A (en) 2016-03-15
DOP2010000099A (es) 2017-04-30
JP2014237659A (ja) 2014-12-18
UA101961C2 (xx) 2013-05-27
US20090099245A1 (en) 2009-04-16
BRPI0816221A2 (pt) 2015-06-16
TW200932747A (en) 2009-08-01
KR20100090769A (ko) 2010-08-17
EP2722046A1 (en) 2014-04-23
AU2008310781B2 (en) 2013-03-28
KR20160039312A (ko) 2016-04-08
MX350019B (es) 2016-12-09
CR11368A (es) 2010-10-25
PA8798401A1 (es) 2009-05-15
PH12012501636A1 (en) 2015-07-10
ES2620299T3 (es) 2017-06-28
TWI422588B (zh) 2014-01-11
DK2722046T3 (en) 2017-03-20

Similar Documents

Publication Publication Date Title
US9580410B2 (en) 2-((R)-2-methylpyrrolidin-2-yl)-1H-benzimidazole-4-carboxamide crystalline form 1
JP2017071617A (ja) ２−（（ｒ）−２−メチルピロリジン−２−イル）−１ｈ−ベンズイミダゾール−４−カルボキサミド結晶型２
JP2011500707A (ja) 結晶性化学療法薬
JP5517940B2 (ja) 結晶性インダゾール由来化学療法薬
US8759538B1 (en) Crystalline chemotherapeutic
HK1197642B (en) 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 1
HK1197642A (en) 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 1

Legal Events

Date Code Title Description
PC41 Official registration of the transfer of exclusive right

Effective date: 20150126

MM4A The patent is invalid due to non-payment of fees

Effective date: 20181011